原始出處紀錄
決策級主要結果 (Topline)
Cartesian 報告 Descartes-08 於 SLE 第二期試驗中達到 100% LLDAS 反應
第二期開放標籤數據顯示，接受 Descartes-08 門診治療的難治性 SLE 患者在第 3 個月達到 100% LLDAS 反應及 2/3 DORIS 緩解。公司將暫停 SLE 進一步開發，以優先推進重症肌無力（第三期）及肌炎（第二期試驗預計於 2026 年上半年啟動）。
關鍵事實
- 申報時間
- 2025年11月13日 下午09:08
- 事件
- 主要結果 (Topline)
- 方向
- 正面
- 來源
- SEC 8-K
- 可信度
- 有出處
- p值
- p<0.01
- DORIS緩解
- 2/3
- LLDAS反應率
- 100%（3/3）
- 肌炎試驗啟動
- 2026年上半年
來源摘錄
EX-99.1 2 pressrelease11132025.htm EX-99.1 Document Exhibit 99.1 Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless adaptive clinical trial design provides potential opportunity for a single pivotal trial expected to commence in 1H26 FREDERICK, Md., Nov. 1